Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Given Imaging signs settlement agreement with Olympus
The company is analyzing the applicable tax, if any, on the payment of $2.33 million to the company, and will revise its 2008 fiscal year earnings per share
The company is analyzing the applicable tax, if any, on the payment of $2.33 million to the company, and will revise its 2008 fiscal year earnings per share
Prior to joining Zelos Therapeutics, Mr Roemer worked at Pharmasset from 1999 through 2008. Before joining Pharmasset, Mr Roemer was a healthcare consultant for Booz-Allen & Hamilton and
The Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study will involve up to 53 subjects with secondary progressive multiple sclerosis who will receive the drug once weekly in
The Phase I/II clinical trial is primarily designed to assess the safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anticancer effects will be documented whenever
Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo. There was no clinically significant decrease in neutrophil counts in the study drug arms. The ACP-104 trial
The randomized double-blind placebo-controlled study with Rhucin was conducted at several sites in the US and Canada. On having an acute hereditary angioedema (HAE) attack, 39 patients were
The study successfully met all four co-primary endpoints. Women treated with Ophena at the 60mg dose showed statistically significant improvements in vaginal dryness and dyspareunia, as well as
The data showed that SGI-1252 selectively inhibits wildtype and mutant JAK2 activity in cancer cell lines, resulting in inhibition of STAT5 phosphorylation as well as a reduction in
Venlafaxine hydrochloride tablets, indicated for the treatment of major depressive disorder, are the generic version of Wyeth’s Effexor tablets. This product is shipping immediately. Currently, Mylan has 92
Under the terms of the settlement the March 2002 agreement is terminated, Hemispherx regains all licensing rights to Ampligen in Spain, Portugal and Andorra, and Hemispherx and Esteve